Luye Pharma was Selected as a Constituent of The MSCI Global Standard Indexes- China Index

May 14, 2015 11:27 JST

Source: Luye Pharma Group Ltd

The Company's Competitiveness in Global Capital Market is Highly Recognized

HONG KONG, May 14, 2015 - (ACN Newswire) - A leading innovative pharmaceutical company with strong R&D capability and global vision in China market-Luye Pharma Group Ltd. (stock code: 2186.HK), is pleased to announce that the Group has been selected as a constituent of Morgan Stanley Capital International ("MSCI") China Index under MSCI Global Standard Indexes and will take effect as of market close on 29 May 2015.

Morgan Stanley Capital International ("MSCI") is a leading provider of global equity indices and benchmark-related products and services to investors worldwide. MSCI indices have become the most widely used international equity benchmarks by institutional investors. As one of the key investment benchmarks of the capital market in China, the importance of MSCI Global Standard Indexes - China Index is widely acknowledged. The constituent stocks of the index are companies with outstanding operational performance and long-term growth potential. Nine securities including Luye will be added to and 4 securities will be deleted from the MSCI China Index.

Mr. LIU Dianbo, Executive Chairman and Chief Executive Officer of Luye Pharma Group Ltd. said, "We are honored to become a constituent stock of the MSCI Global Standard Indexes - China Index. This reflects the recognition from global capital market on the Group's operational performance and business potential, and it demonstrates clearly our strong R&D capabilities and attractive product pipeline. Looking forward, upholding the spirit of innovation and the mission of going global, we endeavor to become a leading global pharmaceutical company. Moreover, we will proactively seize market opportunities, strengthen existing business and increase our market share, and therefore maintain our industry leadership to reward the trust of our investors and to maximize the returns to shareholders."

Source: Luye Pharma Group Ltd
Sectors: Daily Finance, BioTech